Iskos D, Fahy G J, Lurie K G, Sakaguchi S, Adkisson W O, Benditt D G
Cardiac Arrhythmia Center, Department of Medicine, University of Minnesota Medical School, Minneapolis, USA.
Chest. 1997 Oct;112(4):1079-90. doi: 10.1378/chest.112.4.1079.
Atrial fibrillation is the most common cardiac arrhythmia requiring treatment. Limitations of medical treatment have prompted development of nonpharmacologic therapies for this arrhythmia. These are aimed at ventricular rate control during atrial fibrillation, termination of the arrhythmia, and/or prevention of recurrences. Ventricular rate control can be achieved with transcatheter ablation or modification of the atrioventricular node. The MAZE operation is effective in preventing arrhythmia recurrence, but because it requires cardiac surgery, its appeal is limited. Development of the technique for direct transcatheter ablation of atrial fibrillation is eagerly anticipated and may represent the standard curative treatment of the future. In appropriately selected patients, implantable device therapy may play an important role in the treatment of paroxysmal atrial fibrillation.
心房颤动是最常见的需要治疗的心律失常。药物治疗的局限性促使人们开发针对这种心律失常的非药物疗法。这些疗法旨在控制心房颤动期间的心室率、终止心律失常和/或预防复发。通过经导管消融或房室结改良可实现心室率控制。迷宫手术在预防心律失常复发方面有效,但由于它需要心脏手术,其应用受到限制。人们急切期待直接经导管消融心房颤动技术的发展,它可能代表未来的标准根治性治疗方法。在适当选择的患者中,植入式器械治疗可能在阵发性心房颤动的治疗中发挥重要作用。